Esophageal Squamous Cell Carcinoma (ESCC)NCT07567716
Infiltration Pattern of Locally Advanced ESCC
An observational study of Esophageal Squamous Cell Carcinoma (ESCC) and Infiltration, run by Shanghai Chest Hospital at 1 site in China.
Trial summary
Prospectively collect the pathological records of ESCC patients, and analyse the infiltration pattern of ESCC. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Esophageal Squamous Cell Carcinoma (ESCC), Infiltration, Tumour
- What is being tested?
- Esophagectomy
- Type of treatment
- Surgery or procedure
- How many people
- 30 participants
- Where
- 1 siteChina
- Study dates
- 1 Oct 2025to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with c/ycT2-3 esophageal squamous cell carcinoma (ESCC) who underwent McKeown esophagectomy.
Who may be able to join
- cervical or thoracic ESCC
- received esophagectomy
- preoperative stage T2-3
- no viable multiple lesions
- received McKeown esophagectomy
Who cannot join
- Incomplete clinical materials
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Patterns of Microscopic Longitudinal Extension in Esophageal Suqamous Cell Carcinoma
Prospectively collect the pathological records of ESCC patients, and analyse the infiltration pattern of ESCC.
- Being tested
- Esophagectomy
- Keywords
- esophageal squamous cell carcinoma, infiltration pattern, prognosis, resection margin
- Medical subject headings
- Esophageal Squamous Cell Carcinoma, Neoplasms, Margins of Excision
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EsophagectomyOther
Esophagectomy by McKeown method
EsophagectomyProcedure or surgery
Esophagectomy for ESCC
| Study group | Role | What they receive |
|---|---|---|
| esophagectomy group | Receive esophagectomy for treatment Receives: Other: Esophagectomy; Procedure: Esophagectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Infiltration pattern
Direct infiltration length of ESCC beyond macroscopic margin and multiple lesions of ESCC.
Measured: Postoperatively, based on the pathological results of the specimen. Usually, the results will be reported within one month after surgery.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2026
- Study start1 Oct 2025
- Primary completion1 Apr 2026
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Esophageal Squamous Cell Carcinoma (ESCC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai Chest Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zhigang Li, Shanghai Chest Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07567716
- Sponsor's protocol ID
- IS25220
- Status last verified
- Apr 2026
- First submitted
- 22 Apr 2026
- Last updated
- 5 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ma GW, Rong TH, Wu QL, Long H, Fu JH, Lin P, Huang ZF, Zeng CG, Li XD, Zhang X, Zhang LJ, Wang JY, Hu Y, Deng BF. [Giant pathologic section in the study of optimal length of surgical resection for esophageal carcinoma]. Zhonghua Zhong Liu Za Zhi. 2003 Sep;25(5):472-4. Chinese.
PubMed 14575573
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patterns of Microscopic Longitudinal Extension in Esophageal Suqamous Cell Carcinoma
- ClinicalTrials.gov ID
- NCT07567716
- Acronym / sponsor ID
- IS25220
- Keywords
- esophageal squamous cell carcinoma, infiltration pattern, prognosis, resection margin
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Shanghai Chest HospitalUniversity, hospital or other
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- 1 Apr 2026 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 5 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prospectively collect the pathological records of ESCC patients, and analyse the infiltration pattern of ESCC.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| esophagectomy group | – | Other: Esophagectomy, Procedure: EsophagectomyReceive esophagectomy for treatment |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with c/ycT2-3 esophageal squamous cell carcinoma (ESCC) who underwent McKeown esophagectomy.
Key inclusion criteria (5 listed)
- cervical or thoracic ESCC
- received esophagectomy
- preoperative stage T2-3
- no viable multiple lesions
- received McKeown esophagectomy
Key exclusion criteria (1 listed)
- Incomplete clinical materials
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EsophagectomyEsophagectomy by McKeown method | Other | esophagectomy group |
| EsophagectomyEsophagectomy for ESCC | Procedure or surgery | esophagectomy group |
Primary outcome
Infiltration pattern
Time frame: Postoperatively, based on the pathological results of the specimen. Usually, the results will be reported within one month after surgery.
Direct infiltration length of ESCC beyond macroscopic margin and multiple lesions of ESCC.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2026.
- Background: PubMed 14575573Ma GW, Rong TH, Wu QL, Long H, Fu JH, Lin P, Huang ZF, Zeng CG, Li XD, Zhang X, Zhang LJ, Wang JY, Hu Y, Deng BF. [Giant pathologic section in the study of optimal length of surgical resection for esophageal carcinoma]. Zhonghua Zhong Liu Za Zhi. 2003 Sep;25(5):472-4. Chinese.
- Individual participant dataSharing planned: No
Related trials for Esophageal Squamous Cell Carcinoma (ESCC)
RecruitingPhase 2
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Esophageal Squamous Cell Carcinoma, Immunotherapy
RecruitingPhase 2
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
RecruitingPhase 1/2
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 3
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Esophageal Squamous Cell Carcinoma
RecruitingPhase 2
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
Esophageal Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Esophageal Squamous Cell Carcinoma (ESCC) and Infiltration, run by Shanghai Chest Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 5 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Infiltration pattern (time frame: Postoperatively, based on the pathological results of the specimen. Usually, the results will be reported within one month after surgery.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07567716, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2026.